Hercules Capital leads a multi-year growth capital facility of up to $185 million for NorthStar Medical Technologies. NorthStar produces the medical radioisotope Actinium-225 (Ac-225). The financing includes an initial $100 million upfront.
NorthStar will use the funds to scale Ac-225 production and expand its radiopharmaceutical manufacturing capabilities. The investment supports NorthStar's partners in developing and commercializing precision cancer therapies.
The financing follows the FDA's acceptance of NorthStar's Drug Master File for its Ac-225 earlier in 2026.